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From year to year, it is important to get an overview of the occurrence of causative agents in febrile neutropenic patients to deter-
mine the empiric treatment. Thus our aims were to evaluate a four-year period regarding the prevalence of bloodstream infections 
and the most important causative agents. During this period, 1,361 patients were treated in our hematology ward because of various 
hematological disorders. 812 febrile episodes were recorded in 469 patients. At that time, 3,714 blood culture (BC) bottles were sent 
for microbiological investigations, 759 of them gave positive signal. From the majority of positive blood culture bottles (67.1%), 
Gram-positive bacteria, mainly coagulase-negative staphylococci (CNS), were grown. Gram-negative bacteria were isolated from 
32.9% of the positive blood culture bottles, in these cases the leading pathogen was Escherichia coli. The high prevalence of CNS 
was attributed to mainly contamination, while lower positivity rate for Gram-negative bacteria was associated with the use of 
broad-spectrum empiric antibiotic treatment.
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Introduction
Infectious complications, especially bloodstream infec-
tions (BSIs), are major causes of morbidity and mortality 
among patients who suffered from malignant hematologi-
cal diseases and treated with intensive chemotherapeutic 
regimens [1, 2]. In these clinical settings, bacterial cultures 
from blood are of great diagnostic value and the gold stan-
dard to detect bloodstream infections; in addition to this, 
the results of blood cultures provide epidemiological data 
which are useful to determine empiric antibiotic therapy. 
However, the diagnosis of BSIs is still challenging in this 
patient group, because about half of all BSI cases are cul-
ture negative mainly because of the frequently used pro-
phylactic antibiotics [3]. To overcome the inhibitory ef-
fect of antibiotics, special blood culture bottles containing 
resin have been developed; thus, modest increase in the 
sensitivity of culture has been achieved [3]. In the early 
1970s, introducing empiric treatment protocols and anti-
biotic prophylaxis, increasing use of certain chemothera-
peutic drugs associated with frequent oral mucositis, and 
frequent use of central venous catheters have changed 
the spectrum of pathogens in febrile neutropenic patients 
shifting it from Gram-negative to Gram-positive bacteria, 
especially viridans group streptococci and coagulase-neg-
ative staphylococci [3–6].
The aim of this study was to evaluate occurrence of 
bacterial species causing bloodstream infections due to fe-
brile neutropenic episodes in the hematology ward of the 




Between 2005 and 2008, 469 patients with febrile neutro-
penia (230 females and 239 males, median age 60 years) 
were observed in our department with various hemato-
logical diseases. Collected data from patients’ documenta-
tions included demographics of patients, diagnosis, febrile 
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episodes, source of fever and source of infection, neutro-
phil count, and clinical signifi cance of the isolated organ-
ism. Infectious complications were categorized into three 
groups: 1 – fever of unknown origin (FUO), 2 – microbio-
logically documented infection (MDI), and 3 – clinically 
documented infection (CDI).
Definitions
Febrile neutropenia was defi ned if a single oral tempera-
ture was measured higher than 38.3 °C, or temperature 
was 38.0 °C or higher for 1 h. Neutropenia was defi ned 
as absolute neutrophil count (ANC) less than 0.5 × 109/l 
or less than 1.0 × 109/l and rapidly declined below 0.5 × 
109/l [7]. A single positive blood culture (BC) was con-
sidered signifi cant if the isolated strain was clinically rel-
evant cause of the infection. Common skin contaminants 
(CNS, propionibacteria) were considered signifi cant only 
if they could be found in two consecutive BC samples or if 
there were concurrent skin, soft tissue, or catheter-related 
infections. BSI was defi ned as polymicrobial if more than 
1 bacteria grew from BC on the same day. Microbiological 
results were retrieved from the Clinical Microbiological 
Laboratory information system. Medical database of pa-
tients was used to collect information on the hematologic 
diseases, presence of febrile neutropenic episode, duration 
of neutropenia, and source of infection.
Analysis of blood cultures
BC samples were taken at the onset of fever. In patients 
having central venous catheters, BCs were taken from 
both central and peripheral veins. For collection of blood 
culture, the blood culture system (BD Bactec, Beckton 
Dickinson, USA) including aerobic, anaerobic bottles, and 
bottles for fungi was used. After taking blood, bottles were 
immediately placed in an incubator, where these were in-
cubated for 5–14 days depending on the type of the puta-
tive pathogens. In the case of positive signal produced by 
the instrument on the basis of bacterial or fungal growth, 
microscopic examinations (phase contrast microscopy and 
examination of Gram-stained preparations) and culture 
were performed. For aerobic culture, Columbia blood agar 
supplemented with 5% sheep blood (BioMérieux, Marcy 
l’Etoile, France), chocolate agar supplemented with Poly-
ViteX (BioMérieux, Marcy l’Etoile, France), eosin meth-
ylene blue (Lab M, UK) and Sabouraud Chlorampheni-
col (Bio-Rad, France) agars, and, for anaerobic culture, 
Schaedler agar supplemented with 5% sheep blood (Bio-
Mérieux, Marcy l’Etoile, France) were inoculated with 
one drop of blood. Plates were incubated at 37 °C for 24 h 
in a 5% CO2 incubator or 37 °C for 24 h under normal 
atmosphere or at 37 °C for 48 h in an anaerobic cabinet 
(Concept 400; Ruskinn Technology Ltd., Bridgend, UK) 
under a gas composition of 85% N2, 10% H2, and 5% CO2. 
From pure culture, antibiotic susceptibility tests were per-
formed on the basis of Clinical Laboratory Standard Insti-
tute recommendations [8–11].
Antibiotic protocol
At the onset of fever, after taking BC, broad spectrum anti-
biotics were started empirically (piperacillin–tazobactam, 
cefepime, and imipenem or meropenem). Antibiotic dos-
age was modifi ed according to the patient’s renal function. 
Patients were examined once daily by their physician to 
detect potential source of infection. After 48–72 h obser-
vations, the patient’s condition was reevaluated. Changes 
in empiric antibiotic therapy depended on BC results and 
clinical response. In afebrile and culture-negative patients 
with stable clinical state, empiric antibiotic treatment was 
continued until ANC reached 500/μl. Vancomycin was 
used in patients with central venous devices, persistent fe-
ver, and hypotension [12]. On day 4–5, in patients with 
persistent fever suggesting fungal infection on the basis of 
clinical signs and computed tomography (CT) scans, am-
photericin B was applied.
Results
During the four-year study period, 1,361 patients were 
treated in the hematology ward because of various he-
matological diseases. A total of 812 febrile episodes were 
recorded in 469 (34.5%) patients, and blood was collect-
ed for microbiological culture. Of the 469 patients, 128 
(27.3%) had acute myeloid leukemia, 85 (18.1%) non-
Hodgkin’s lymphoma, 66 (14.1%) multiple myeloma, 64 
(13.6%) chronic lymphocytic leukemia, 41 (8.7%) acute 
lymphoblastic leukemia, and 85 (18.1%) others (Hodg-
kin’s lymphoma, myelodysplastic syndrome, chronic 
myeloprolipherative disorders etc.) (Table1). Altogether, 
3,714 blood culture bottles, 6.5 bottles/patient (ranging 
2–12), were sent to the laboratory. In 126 (27%) of 469 pa-
tients, only one pair of blood culture bottles was taken by 
febrile episodes. Clinically documented infections could 
be observed in 430 of 812 febrile episodes (52.95%). The 
majority of them localized to the lung (39.5%). Colitis and 
skin and soft tissue infections were the second and third 
most common infections.
During the microbiological culture, 759 (20.4%) of 
3,714 blood culture bottles gave positive signals. From 
the majority of positive blood culture bottles (509 bottles 
(67.1%)), Gram-positive bacteria were cultured. Among 
Gram-positive bacteria, the most frequent isolates were 
coagulase-negative staphylococci (65%), Staphylococcus 
aureus (10%), Enterococcus spp. (6.7%), Popionibacte-
rium acnes (5.7%), β-hemolytic streptococci (3.1%), Strep-
tococcus pneumoniae (2.8%), α-hemolytic streptococci 
(2.4%), Clostridium spp. (1.4%), and others (3%) (includ-
ing Listeria monocytogenes, Nocardia farcinica, Gemella 
spp., Micrococcus spp., Brevibacterium spp., and Gram-
positive nonidentifi ed bacteria) (Table 2). Gram-negative 
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bacteria were isolated from 250 (32.9%) blood culture 
bottles. High prevalence of Escherichia coli (52%) could 
be detected in these specimens, while 14% of samples con-
tained Pseudomonas aeruginosa, 9.6% Klebsiella spp., 
8% Enterobacter spp., 3.6% Citrobacter spp., 2% Steno-
trophomonas maltophilia, 1.6% Acinetobacter spp., and 
1.6% Fusobacterium spp. (Table 3). Only six bottles 
proved to be positive for fungi during the examined pe-
riod; in two cases, Candida albicans and also, in two bot-
tles, Candida tropicalis could be detected, while two other 
bottles were positive for Cryptococcus spp.
Among Gram-positive isolates, coagulase-negative 
staphylococci (CNS) were identifi ed in 331 cases. These 
blood culture samples were collected from 161 febrile epi-
sodes of 149 patients. In 50 febrile neutropenic episodes, 
CNS were relevant as a causative agent of fever because 
of the coexistence of skin, soft tissue, and central venous 
catheter-related infections. In the case of the remaining 
111 cases, contamination could be the source of CNS.
Among rarely isolated pathogens, Listeria sp. was 
identifi ed from one patient with acute myeloid leukemia 
(AML) due to second relapse in 2006. The patient had 
clinically documented pneumonia and was treated with 
ampicillin. In 2006 and 2008, Burkholderia cepacea was 
identifi ed from two patients. One of them was observed 
with AML and did not receive any chemotherapeutic treat-
ment. Blood culture sample was taken from peripheral 
vein. In this case, the patient was treated empirically with 
levofl oxacin. The other patient suffered from relapsed 
Hodgkin lymphoma and was treated according to ESHAP 
chemotherapeutic regimen (combination of high-dose 
cytosine-arabinosid, methylprednisolone, cisplatin, and 
etoposide) through the central venous line. Two pairs of 
blood culture samples were taken due to febrile episode 
from catheter, and B. cepacea was grown from each sam-
ples. N. farcinica was isolated from a patient with large 
granular lymphocytic (LGL) leukemia. He underwent six 
cycles of combined chemotherapeutic treatment (cyclo-
Table 1. Patient characteristics at admission to hematology ward between 2005 and 2008
Patient characteristics Number of patients
N = 469 (%)





 Acute myeloid leukaemia 128 (27.3)
 Non-Hodgkin’s lymphoma 85 (18.1)
 Multiple myeloma 66 (14.1)
 Chronic lymphocytic leukaemia 64 (13.6)
 Acute lymphoblastic leukaemia 41 (8.7)
Others (chronic myeloprolipherative disorders, 
myelodysplastic syndrome, Hodgkin’s lymphoma, etc.)
85 (18.1)
Table 2. Annually identified Gram-positive bacteria from blood culture
Isolated strain Number of isolated strains according to years Total
N = 509 (%)2005 2006 2007 2008
Coagulase-negative staphylococci 94 73 86 78 331 (65)
S. aureus 25 6 11 9 51 (10)
Enterococcus spp. 6 9 5 14 34 (6.7)
P. acnes 13 10 2 4 29 (5.7)
Beta-hemolytic streptococci 10 5 1 0 16 (3.1)
S. pneumoniae 5 0 0 9 14 (2.8)
Alfa-hemolytic streptococci 0 7 1 4 12 (2.4)
Clostridium spp. 2 4 0 1 7 (1.4)
Others (L. monocytogenes, N. far-
ci nica, Gemella spp., Micrococcus 
spp., Brevibacterium spp., etc.)
4 6 2 3 15 (3)
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phosphamide, vincristine, and prednisolone) and later had 
long term steroid therapy due to Coombs positive hemo-
lytic anemia and active hemolytic events. On hospital ad-
mission, CT scan showed multiple lesions with perifocal 
oedema, but stereotactic core biopsy from lesions could 
not be performed because of the patient’s severe clinical 
status. From one pair of blood culture, N. farcinica was 
isolated, but the patient died before adequate therapy could 
start. During the examined period, four cases of bacteremia 
caused by Fusobacterium nucleatum could be observed in 
this patient group. Two patients had acute myeloid leuke-
mia, one patient had acute myelomonocytic leukemia, and 
one patient suffered from pre-B-cell lymphoblastic leuke-
mia. Two patients received chemotherapy before positive 
blood culture; one of them had oral mucositis associated 
with the applied chemotherapy.
Discussion
Febrile neutropenia is the most important complication of 
chemotherapy in patients with hematologic malignancy. 
This may have infl uence on the applied chemotherapy; 
dose reduction or treatment delays can be observed fre-
quently when febrile neutropenia is present, and this also 
has unfavorable long-term outcome in otherwise curable 
malignancy [13].  Bloodstream infections are among the 
most important bacterial infections, despite the develop-
ment in the fi eld of microbiological diagnosis and anti-
microbial therapy; these infections are responsible for the 
large proportion of nosocomial infections worldwide. In 
the early 1960s, the importance of bloodstream infection 
in neutropenic patients had been recognized; thus, empiri-
cal treatment protocols were established for mainly Gram-
negative bacteria [14]. Later, the spectrum of pathogens 
associated with BSI shifted from Gram-negative bacteria 
to Gram-positive bacteria due to the increased use of anti-
biotic prophylaxis and indwelling catheters allowing colo-
nizations and infections with the skin fl ora. Nowadays, the 
most common pathogens isolated from blood are coagu-
lase-negative staphylococci and various antibiotic-resis-
tant bacteria. In the majority of cases, the source of these 
infections is unknown in spite of various efforts to fi nd 
them. Recognition of changes in the epidemiology of BSIs 
is very important to modify the antibiotic policy because, 
on the basis of these fi ndings, we can reduce the infection-
related morbidity and mortality [15, 16]. During the four-
year study period, the incidence of bacteremia was 20.4%. 
Similar fi ndings were reported in the literature; Klastersky 
et al. showed that the incidence of bacteremia was 23% 
when they examined over two thousand patients with fe-
brile neutropenia in cancer patients, while Viscoli et al. 
found that bacteremia occurred in 29% of patients with fe-
brile neutropenia [17, 18]. Our fi ndings correlated with the 
abovementioned literature data because, from the majority 
of blood culture bottles (13.7%), Gram-positive bacteria 
were isolated. Sixty-fi ve percent of Gram-positive bacteria 
belonged to coagulase-negative staphylococci. However, 
in a study by Winston et al. in North America, Gram-
negative bacteria (55.6%) [19] were responsible for the 
majority of bacteremia in febrile neutropenic patients. At 
the same time, other authors from Italy or France showed 
that the most important isolates in neutropenic patients 
are Gram-positive bacteria, including coagulase-negative 
staphylococci or streptococci, while Gram-negative or-
ganisms including E. coli or Klebsiella spp. and P. aeru-
ginosa constitute smaller portion of the isolates [20, 21]. 
In our case, the most frequently used empirical treatment 
in this patient group is piperacillin–tazobactam or, if the 
patient has colitis or the possibility of abdominal infection 
is arisen, imipenem or meropenem is the frequently used 
antibiotic. Thus, the increased incidence of Gram-positive 
bacteria can be explained by the applied empirical anti-
biotic treatment, while the presence of coagulase-negative 
staphylococci could be attributed to the frequently used 
central venous catheters. The incidence of bacterial spe-
cies in blood cultures can be infl uenced by the applied 
chemotherapy. In our case, 30% of patients with acute 
Table 3. Annually isolated Gram-negative bacteria from blood culture bottles
Isolated strain Number of isolated strains according to years Total
N = 509 (%)2005 2006 2007 2008
E. coli 22 38 41 29 130 (52)
P. aeruginosa 6 6 10 13 35 (14)
Klebsiella spp. 0 10 6 8 24 (9.6)
Enterobacter spp. 7 3 0 1 20 (8)
Citrobacter spp. 2 3 2 2 9 (3.6)
S. maltophilia 0 0 2 3 5 (2)
Acinetobacter spp. 0 1 1 2 4 (1.6)
Fusobacterium spp. 0 2 2 0 4 (1.6)
Others (H. influenzae, A. xylos-
oxidans, P. mirabilis, Salmonella 
spp., Neisseria spp., Gram-
negative non-identified rods, etc.)
5 4 5 5 19 (7.6)
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leukemia received high-dose Ara-C chemotherapy, and 
15% and 12% of patients were treated with fl udarabin and 
Ara-C plus idarubicin, respectively. On the basis of litera-
ture data, increasing prevalence of Gram-positive cocci in 
febrile neutropenic patients could be observed after high-
dose cytarabine chemotherapy; this was confi rmed by our 
results [21]. Cordonnier et al. showed that the prevalence 
of staphylococci is higher than the prevalence of strep-
tococci and enterococci in febrile neutropenic patients 
[21]. Similarly, our results confi rmed this because, among 
Gram-positive bacteria, the majority of the isolated strains 
were coagulase-negative staphylococci; 6.7% and only 
2.4% of Gram-positive bacteria belonged to Enterococcus 
spp. and β-hemolytic streptococci, respectively. A total of 
331 blood culture samples proved to be positive for coag-
ulase-negative staphylococci and were collected from 161 
febrile episodes of 149 patients. In 50 febrile neutropenic 
episodes, coagulase-negative staphylococci were relevant 
pathogen of fever because of the coexistence of skin, soft 
tissue, and central venous catheter-related infection. The 
remaining 111 cases were supposed to be contamination.
From 32.9% of positive blood cultures bottles, Gram-
negative bacteria were cultured; the majority of these 
proved to be positive for E. coli (52%). The second most 
common isolate was P. aeruginosa (14%), while the 
third one was Klebsiella spp. (9.6%). Similar fi ndings by 
Ramphal could be found [16]. In this review, the results 
of four articles were analyzed, and, among Gram-negative 
organisms, the most important pathogens were also E. coli, 
Klebsiella spp., and P. aeruginosa [16].
Among rarely isolated bacteria, Achromobacter xylos-
oxidans and Burkholderia cepacia are usually associ-
ated with catheter-related sepsis, while S. maltophilia can 
cause mainly nosocomial bacteremia [22] and the possible 
source of Haemophilus infl uenzae, Neisseria spp., and 
Gemella spp. is the damaged oral mucosa. Because of the 
possible presence of unusual pathogens, such as anaerobic 
bacteria or fastidious microorganisms, the use of various 
blood culture bottles including anaerobic bottles should be 
considered.
Because of its rapid progression of infection in febrile 
neutropenic patients and diffi culties in distinguishing in-
fection from noninfected patients on the basis of clinical 
presentation in this patient group, the use of empirical an-
tibiotic treatment is essential and may provide the possibil-
ity to reach better outcome.
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